Genomic analysis of 11,555 probands identifies 60 dominant congenital heart disease genes

Michael C. Sierant, Sheng Chih Jin, Kaya Bilgüvar, Sarah U. Morton, Weilai Dong, Wei Jiang, Ziyu Lu, Boyang Li, Francesc López‐Giráldez, Irina Tikhonova, Xue Zeng, Qiongshi Lu, Jungmin Choi, Junhui Zhang, Carol Nelson‐Williams, James Knight, Hongyu Zhao, Junyue Cao, Shrikant Mane, Stanley C. Sedore, Peter J. Gruber, Monkol Lek, Elizabeth Goldmuntz, John Deanfield, Anna Giardini, Seema Mital, Mark W. Russell, J. William Gaynor, Eileen King, Michael Wagner, Deepak Srivastava, Yufeng Shen, Daniel Bernstein, George A. Porter, Jane W. Newburger, Jonathan G. Seidman, Amy E. Roberts, Mark Yandell, H. Joseph Yost, Martin Tristani‐Firouzi, Richard D. Kim, Wendy K. Chung, Bruce D. Gelb, Christine E. Seidman, Martina Brueckner, Richard P. LiftonProceedings of the National Academy of Sciences 2025 · DOI

TL;DR

This study analyzed the genomes of over 11,500 individuals with congenital heart disease (CHD), identifying 60 genes significantly associated with the condition. These genes explain over 10% of CHD cases and reveal a complex interplay between cardiac defects, extracardiac abnormalities, and neurodevelopmental disorders, highlighting the potential for improved genetic diagnostics and early intervention.

What Problem Does This Paper Address?

Congenital heart disease (CHD) is a major cause of infant mortality and lifelong morbidity. While genetic factors are known to play a role, the genetic architecture of CHD is complex and not fully understood. Previous studies, often limited by sample size or specific genetic variant types (like de novo mutations), had identified only a handful of genes strongly associated with CHD. The challenge lies in identifying a comprehensive set of genes that contribute to the diverse spectrum of CHD, understanding how these genetic variations manifest as different phenotypes (including extracardiac issues and neurodevelopmental delays), and accounting for both inherited and de novo mutations. This paper aims to significantly expand the known genetic landscape of CHD by analyzing a large cohort with a broad range of genetic data.

Methods

The researchers employed a multi-pronged approach:

  • Molecular Inversion Probe Sequencing (MIPseq): This cost-effective method was used to sequence a targeted panel of 248 candidate CHD genes in a large number of probands. This allowed for high-throughput, precise sequencing of specific genomic regions.
  • Whole Exome Sequencing (WES): WES data was also utilized, particularly for parent-offspring trios, to identify de novo mutations (DNMs) and inherited variants.
  • Variant Calling and Annotation: Standard bioinformatics pipelines (GATK, Freebayes, ANNOVAR) were used to identify and annotate genetic variants, focusing on loss-of-function (LOF) and damaging missense (D-mis) mutations.
  • Statistical Analysis:
    • Meta-analysis: A meta-analysis combined data from DNMs and rare transmitted/unphased variants (TUVs) to identify genes with a significant burden of damaging mutations.
  • Case-control analysis: Frequencies of rare damaging variants in probands were compared to large control datasets (gnomAD).
  • Transmission Disequilibrium Test (TDT): This was used to assess whether damaging variants were preferentially transmitted from parents to affected offspring in trio data.
  • Phenotype Stratification: Statistical methods were used to associate specific genes with particular cardiac lesions, extracardiac (EC) abnormalities, and neurodevelopmental delay (NDD).
  • Single-cell Gene Expression Analysis: This was used to correlate gene expression patterns (in mouse gastrulation) with specific CHD phenotypes (isolated CHD vs. NDD & EC).

The novelty lies in the scale of the cohort, the combination of MIPseq and WES for comprehensive genetic data, and the sophisticated statistical methods used to integrate different types of genetic variants and link them to a wide array of clinical phenotypes.

Datasets

  • Proband Cohort: 11,555 CHD probands, including 5,929 sequenced with MIPseq and 5,626 with WES. This cohort also included 3,887 parent-offspring trios and 7,668 singletons.
  • Control Cohort: 133,743 individuals from the gnomAD database (WES/WGS data).
  • Prior Data: Data from previous studies, including 1,213 parent-offspring trios from the Pediatric Cardiac Genomics Consortium (PCGC) and the Pediatric Heart Network (PHN) cohorts, were used to inform the selection of candidate genes.
  • Expression Data: Single-cell RNA-sequencing data from mouse gastrulation and human fetal development datasets were used to analyze gene expression patterns.

Key Insights and Ideas

  • Expanding the CHD Gene Landscape: The study significantly increases the number of known dominant CHD genes from a handful to 60, implicating a broader genetic basis for the condition.
  • Dual Role of De Novo and Transmitted Variants: Both de novo mutations and inherited rare variants contribute substantially to CHD risk, with roughly equal contributions from each in trios.
  • Pleiotropy of CHD Genes: Many identified genes are associated with a wide range of phenotypes, not just cardiac defects. Genes expressed broadly in the brain are linked to neurodevelopmental delay (NDD), while those restricted to the heart are more associated with isolated CHD.
  • Specific Variant Types Matter: The study highlights that the type of mutation within a gene can influence the phenotype. For example, cysteine-altering mutations in NOTCH1's EGF domains are specifically enriched in tetralogy of Fallot (TOF) and conotruncal defects, unlike LOF variants.
  • Incomplete Penetrance is Common: Even with pathogenic variants, not all individuals develop clinical CHD, suggesting complex genetic and environmental interactions, or subclinical disease.
  • Clinical Diagnosis Gaps: Many probands with characteristic mutations causing syndromic CHD were not clinically diagnosed, often due to subtle or absent cardinal phenotypes, underscoring the need for genetic testing.

Key Results

  • 60 Dominant CHD Genes Identified: The study identified 60 genes with a significant burden of heterozygous damaging variants contributing to CHD.
  • 10.1% of Probands Explained: Variants in these 60 genes accounted for CHD in 10.1% of the 11,555 probands.
  • De Novo Mutations (DNMs) Contribution: DNMs in these genes accounted for 58% of the total DNM signal.
  • Transmitted Variants' Role: Transmitted variants contributed to an additional 5.4% of probands.
  • Phenotypic Heterogeneity:
    • 33 genes were linked to a single CHD subtype.
  • 12 genes were associated with 2-4 subtypes.
  • 7 genes were associated with isolated CHD.
  • 37 genes were associated with 1 or more extracardiac abnormalities.
  • MYH6 Variants: Transmitted damaging missense variants in MYH6 were enriched in multiple CHD phenotypes and accounted for approximately 1% of all probands.
  • NOTCH1 Cysteine Variants: Cysteine-altering mutations in NOTCH1's EGF domains showed a significant enrichment in TOF and CTD, with a 250-fold enrichment in EGF domain #5.
  • Syndromic CHD Diagnosis: A significant proportion of probands with mutations in syndromic genes (e.g., CHD7, KMT2D, PTPN11) were not clinically diagnosed with their respective syndromes, highlighting diagnostic challenges.

Limitations and Future Work

  • Missense Variant Interpretation: Accurately assessing the pathogenicity of rare missense variants remains a challenge.
  • NDD Assessment: Questionnaire-based assessment of NDD in young probands may underestimate the true frequency of these conditions.
  • Sample Size for Rare Variants: While large, the cohort may still be underpowered to detect associations for very rare variants or genes with low mutation rates.
  • Non-coding Variants: The study primarily focused on coding variants; the role of rare non-coding variants in CHD is not fully explored here.
  • Future Directions:
    • Larger cohorts are needed to further expand CHD gene discovery and refine phenotype associations.
  • Genome-wide association studies (GWAS) could help assess the role of common variants in variable expressivity.
  • Continued development of computational tools for variant interpretation is crucial.
  • The findings support the increased use of molecular diagnostics for early risk assessment and intervention in CHD.

Summary updated

Abstract

Congenital heart disease (CHD) is a leading cause of infant mortality. We analyzed de novo mutations (DNMs) and very rare transmitted/unphased damaging variants in 248 prespecified genes in 11,555 CHD probands. The results identified 60 genes with a significant burden of heterozygous damaging variants. Variants in these genes accounted for CHD in 10.1% of probands with similar contributions from de novo and transmitted variants in parent-offspring trios that showed incomplete penetrance. DNMs in these genes accounted for 58% of the signal from DNMs. Thirty-three genes were linked to a single CHD subtype while 12 genes were associated with 2 to 4 subtypes. Seven genes were only associated with isolated CHD, while 37 were associated with 1 or more extracardiac abnormalities. Genes selectively expressed in the cardiomyocyte lineage were associated with isolated CHD, while those widely expressed in the brain were also associated with neurodevelopmental delay (NDD). Missense variants introducing or removing cysteines in epidermal growth factor (EGF)-like domains of NOTCH1 were enriched in tetralogy of Fallot and conotruncal defects, unlike the broader CHD spectrum seen with loss of function variants. Transmitted damaging missense variants in <i>MYH6</i> were enriched in multiple CHD phenotypes and account for ~1% of all probands. Probands with characteristic mutations causing syndromic CHD were frequently not diagnosed clinically, often due to missing cardinal phenotypes. CHD genes that were positively or negatively associated with development of NDD suggest clinical value of genetic testing. These findings expand the understanding of CHD genetics and support the use of molecular diagnostics in CHD.
BibTeX
@inproceedings{sierant2025genomic,
  author = {Michael C. Sierant and Sheng Chih Jin and Kaya Bilgüvar and Sarah U. Morton and Weilai Dong and Wei Jiang and Ziyu Lu and Boyang Li and Francesc López‐Giráldez and Irina Tikhonova and Xue Zeng and Qiongshi Lu and Jungmin Choi and Junhui Zhang and Carol Nelson‐Williams and James Knight and Hongyu Zhao and Junyue Cao and Shrikant Mane and Stanley C. Sedore and Peter J. Gruber and Monkol Lek and Elizabeth Goldmuntz and John Deanfield and Anna Giardini and Seema Mital and Mark W. Russell and J. William Gaynor and Eileen King and Michael Wagner and Deepak Srivastava and Yufeng Shen and Daniel Bernstein and George A. Porter and Jane W. Newburger and Jonathan G. Seidman and Amy E. Roberts and Mark Yandell and H. Joseph Yost and Martin Tristani‐Firouzi and Richard D. Kim and Wendy K. Chung and Bruce D. Gelb and Christine E. Seidman and Martina Brueckner and Richard P. Lifton},
  title = {{Genomic analysis of 11,555 probands identifies 60 dominant congenital heart disease genes}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2420343122},
}
Figure